# CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

> **NCT07168486** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **University of Maryland, Baltimore** · enrollment: 15 (estimated)

## Conditions studied

- B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma (DLBCL)
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Follicular Lymphoma
- Transformed Follicular Lymphoma (tFL)
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Richter Transformation
- Marginal Zone Lymphoma

## Interventions

- **BIOLOGICAL:** CD19.20.22 CAR T cells
- **DRUG:** Fludarabine and Cyclophosphamide

## Key facts

- **NCT ID:** NCT07168486
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-10-28
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07168486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07168486, "CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07168486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*